Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial – The Lancet

Commentary: Non-hormonal therapy reduces hot flashes and night sweats in women who have been diagnosed with breast cancer – Monash University